nach oben

Journal of Neuro-Oncology

Erschienen in:

11.12.2017 | Laboratory Investigation

P21^Waf1/Cip1 and p27^Kip1 are correlated with the development and invasion of prolactinoma

verfasst von: Wei Dong, Jianhua Li, Qian Liu, Chunhui Liu, Chuzhong Li, Guidong Song, Haibo Zhu, Hua Gao, Yazhuo Zhang

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Cell cycle control can prevent excessive proliferative response in the pituitary homeostasis. Cyclin dependent kinases (Cdks) are modulated by cyclins or Cdk inhibitors, such as p21 and p27, which can regulate cell cycle progression from the G1 to S phases. This study was conducted to evaluate the levels and the promoter region methylation status of p21 and p27 in prolactinomas (PRL) and analyze their association with clinicopathologic features. We found high-p21 level cases were featured by 5/23 and H-scores 142.3 ± 23.7 in invasive-PRL specimens, and 19/25 and 221.3 ± 45.4 in non-invasive specimens (x² = 14.11, p = 0.000), while high-p27 level cases were featured by 6/23 and H-scores 129.8 ± 31.1 in invasive-PRL specimens, and 18/25 and 197.1 ± 46.6 in non-invasive specimens (x² = 10.11, p = 0.001). A similar trend was also observed for p21 and p27 protein levels in PRL specimens through western-blot (P < 0.01, respectively). The Ki-67 index was much higher in invasive specimens than in non-invasive specimens (x² = 10.10, p = 0.001). Average 33 CpG sites per sample were analyzed by using MALDI-TOF Mass array, and 7/33 CpG sites methylation levels of p27 were higher than 50%. There existed significant differences in 4 CpG sites between invasive specimens and non-invasive specimens (p < 0.01). We found that D2 receptor was closely correlated with p21 levels (P < 0.05, r = 0.567) and p27 levels (P < 0.05, r = 0.591). In PRL, the deficiency in p21 and p27 contributed to the tumor proliferation and migration and Cdk inhibitors may be used as a new therapeutic approach.

Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metabol 91:4769–4775. https://doi.org/10.1210/jc.2006-1668 CrossRef

Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol 72:377–382. https://doi.org/10.1111/j.1365-2265.2009.03667.x CrossRef

Colao A, Savastano S (2011) Medical treatment of prolactinomas. Nat Rev Endocrinol 7:267–278. https://doi.org/10.1038/nrendo.2011.37 CrossRefPubMed

Clarke AR, Maandag ER, van Roon M, van der Lugt NM, van der Valk M, Hooper ML, Berns A, te Riele H (1992) Requirement for a functional Rb-1 gene in murine development. Nature 359:328–330. https://doi.org/10.1038/359328a0 CrossRefPubMed

Bi WL, Horowitz P, Greenwald NF, Abedalthagafi M, Agarwalla PK, Gibson WJ, Mei Y, Schumacher SE, Ben-David U, Chevalier A, Carter S, Tiao G, Brastianos PK, Ligon AH, Ducar M, MacConaill L, Laws ER Jr, Santagata S, Beroukhim R, Dunn IF (2017) Landscape of genomic alterations in pituitary adenomas. Clin Cancer Res 23:1841–1851. https://doi.org/10.1158/1078-0432.CCR-16-0790 CrossRefPubMed

Martin A, Odajima J, Hunt SL, Dubus P, Ortega S, Malumbres M, Barbacid M (2005) Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell 7:591–598. https://doi.org/10.1016/j.ccr.2005.05.006 CrossRefPubMed

Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA (1992) Effects of an Rb mutation in the mouse. Nature 359:295–300. https://doi.org/10.1038/359295a0 CrossRefPubMed

Quereda V, Malumbres M (2009) Cell cycle control of pituitary development and disease. J Mol Endocrinol 42:75–86. https://doi.org/10.1677/JME-08-0146 CrossRefPubMed

Malumbres M, Barbacid M (2001) To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1:222–231. https://doi.org/10.1038/35106065 CrossRefPubMed

10.

Morgan DO (1995) Principles of CDK regulation. Nature 374:131–134. https://doi.org/10.1038/374131a0 CrossRefPubMed

11.

Sherr CJ (1994) G1 phase progression: cycling on cue. Cell 79:551–555CrossRefPubMed

12.

Reed SI, Bailly E, Dulic V, Hengst L, Resnitzky D, Slingerland J (1994) G1 control in mammalian cells. J Cell Sci Suppl 18:69–73CrossRefPubMed

13.

Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501–1512CrossRefPubMed

14.

Ikeda H, Yoshimoto T, Shida N (1997) Molecular analysis of p21 and p27 genes in human pituitary adenomas. Br J Cancer 76:1119–1123CrossRefPubMedPubMedCentral

15.

Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, Su L, Xiong Y (1998) CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 12:2899–2911CrossRefPubMedPubMedCentral

16.

Franklin DS, Godfrey VL, O’Brien DA, Deng C, Xiong Y (2000) Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol 20:6147–6158CrossRefPubMedPubMedCentral

17.

Lee MY, Heo JS, Han HJ (2006) Dopamine regulates cell cycle regulatory proteins via cAMP, Ca(2+)/PKC, MAPKs, and NF-kappaB in mouse embryonic stem cells. J Cell Physiol 208:399–406. https://doi.org/10.1002/jcp.20674 CrossRefPubMed

18.

Roncaroli F, Scheithauer BW (2007) Papillary tumor of the pineal region and spindle cell oncocytoma of the pituitary: new tumor entities in the 2007 WHO Classification. Brain Pathol 17:314–318. https://doi.org/10.1111/j.1750-3639.2007.00081.x CrossRefPubMed

19.

Malumbres M, Barbacid M (2005) Mammalian cyclin-dependent kinases. Trends Biochem Sci 30:630–641. https://doi.org/10.1016/j.tibs.2005.09.005 CrossRefPubMed

20.

Musat M, Vax VV, Borboli N, Gueorguiev M, Bonner S, Korbonits M, Grossman AB (2004) Cell cycle dysregulation in pituitary oncogenesis. Front Hormon Res 32:34–62CrossRef

21.

Gruppetta M, Formosa R, Falzon S, Ariff Scicluna S, Falzon E, Degeatano J, Vassallo J (2017) Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas. Pituitary 20(3):358–371. https://doi.org/10.1007/s11102-017-0803-0 CrossRefPubMed

22.

Liu NA, Jiang H, Ben-Shlomo A, Wawrowsky K, Fan XM, Lin S, Melmed S (2011) Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proc Natl Acad Sci USA 108(20):8414–8419. https://doi.org/10.1073/pnas.1018091108 CrossRefPubMedPubMedCentral

23.

Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K (1996) Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707–720CrossRefPubMed

24.

Nakayama K, Nakayama K (1998) Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development. Bioessays 20:1020–1029. https://doi.org/10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D CrossRefPubMed

25.

Alt JR, Gladden AB, Diehl JA (2002) p21(Cip1) promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export. J Biol Chem 277:8517–8523. https://doi.org/10.1074/jbc.M108867200 CrossRefPubMed

26.

Chen J, Jackson PK, Kirschner MW, Dutta A (1995) Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374:386–388. https://doi.org/10.1038/374386a0 CrossRefPubMed

27.

Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ (1999) The p21(Cip1) and p27(Kip1) CDK ‘inhibitors’ are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 18:1571–1583. https://doi.org/10.1093/emboj/18.6.1571 CrossRefPubMedPubMedCentral

28.

Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC, Langan TA, Sclafani RA, Lange CA, Horwitz KB (1997) Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol 11:1593–1607. https://doi.org/10.1210/mend.11.11.0006 CrossRefPubMed

29.

Dai L, Liu Y, Liu J, Wen X, Xu Z, Wang Z, Sun H, Tang S, Maguire AR, Quan J, Zhang H, Ye T (2013) A novel CyclinE/CyclinA-CDK Inhibitor targets p27Kip1 degradation, cell cycle progression and cell survival: implications in cancer therapy. Cancer Lett 333(1):103–112. https://doi.org/10.1016/j.canlet.2013.01.025 CrossRefPubMed

30.

Chesnokova V, Zonis S, Rubinek T, Yu R, Ben-Shlomo A, Kovacs K, Wawrowsky K, Melmed S (2007) Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res 67:10564–10572. https://doi.org/10.1158/0008-5472.CAN-07-0974 CrossRefPubMedPubMedCentral

31.

Patel SD, Tran AC, Ge Y, Moskalenko M, Tsui L, Banik G, Tom W, Scott M, Chen L, Van Roey M, Rivkin M, Mendez M, Gyuris J, McArthur JG (2000) The p53-independent tumoricidal activity of an adenoviral vector encoding a p27-p16 fusion tumor suppressor gene. Mol Ther 2:161–169. https://doi.org/10.1006/mthe.2000.0106 CrossRefPubMed

32.

Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ (1995) Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552–557. https://doi.org/10.1038/377552a0 CrossRefPubMed

33.

Jin L, Qian X, Kulig E, Sanno N, Scheithauer BW, Kovacs K, Young WF Jr, Lloyd RV (1997) Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol 151:509–519PubMedPubMedCentral

34.

Lloyd RV, Jin L, Qian X, Kulig E (1997) Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol 150:401–407PubMedPubMedCentral

35.

Sadeghipour A, Mahouzi L, Salem MM, Ebrahim-Nejad S, Asadi-Lari M, Radfar A, Filip I, Babaheidarian P (2017) Ki67 labeling correlated with invasion but not with recurrence. Appl Immunohistochem Mol Morphol 25:341–345. https://doi.org/10.1097/PAI.0000000000000303 CrossRefPubMed

36.

Tortosa F, Webb SM (2016) Atypical pituitary adenomas: 10 years of experience in a reference centre in Portugal. Neurologia 31:97–105. https://doi.org/10.1016/j.nrl.2015.06.010 CrossRefPubMed

37.

Bloom J, Pagano M (2003) Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 13:41–47CrossRefPubMed

38.

Ortega S, Malumbres M, Barbacid M (2002) Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Et Biophys Acta 1602:73–87

39.

Topley GI, Okuyama R, Gonzales JG, Conti C, Dotto GP (1999) p21(WAF1/Cip1) functions as a suppressor of malignant skin tumor formation and a determinant of keratinocyte stem-cell potential. Proc Natl Acad Sci USA 96:9089–9094CrossRefPubMedPubMedCentral

40.

Yang WC, Mathew J, Velcich A, Edelmann W, Kucherlapati R, Lipkin M, Yang K, Augenlicht LH (2001) Targeted inactivation of the p21(WAF1/cip1) gene enhances Apc-initiated tumor formation and the tumor-promoting activity of a Western-style high-risk diet by altering cell maturation in the intestinal mucosal. Cancer Res 61:565–569PubMed

41.

Hunter T, Pines J (1994) Cyclins and cancer. II: cyclin D and CDK inhibitors come of age. Cell 79:573–582CrossRefPubMed

42.

Philipp-Staheli J, Payne SR, Kemp CJ (2001) p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 264:148–168. https://doi.org/10.1006/excr.2000.5143 CrossRefPubMed

43.

Slingerland J, Pagano M (2000) Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 183:10–17. https://doi.org/10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I CrossRefPubMed

44.

Sesselmann S, Söder S, Voigt R, Haag J, Grogan SP, Aigner T (2019) DNA methylation is not responsible for p21WAF1/CIP1 down-regulation in osteoarthritic chondrocytes. Osteoarthritis Cartilage 17(4):507–512. https://doi.org/10.1016/j.joca.2008.09.006 CrossRef

45.

Delgrange E, Sassolas G, Perrin G, Jan M, Trouillas J (2005) Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochir 147:751–757. https://doi.org/10.1007/s00701-005-0498-2 [discussion 757–758]CrossRefPubMed

46.

Gao H, Wang F, Lan X, Li C, Feng J, Bai J, Cao L, Gui S, Hong L, Zhang Y (2015) Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas. BMC Cancer 15:272. https://doi.org/10.1186/s12885-015-1267-0 CrossRefPubMedPubMedCentral

47.

Choi EY, Jeong D, Park KW, Baik JH (1999) G protein-mediated mitogen-activated protein kinase activation by two dopamine D2 receptors. Biochem Biophys Res Commun 256:33–40CrossRefPubMed

48.

Oak JN, Lavine N, Van Tol HH (2001) Dopamine D(4) and D(2L) receptor stimulation of the mitogen-activated protein kinase pathway is dependent on trans-activation of the platelet-derived growth factor receptor. Mol Pharmacol 60:92–103CrossRefPubMed

49.

Pellegrini-Bouiller I, Morange-Ramos I, Barlier A, Gunz G, Figarella-Branger D, Cortet-Rudelli C, Grisoli F, Jaquet P, Enjalbert A (1996) Pit-1 gene expression in human lactotroph and somatotroph pituitary adenomas is correlated to D2 receptor gene expression. J Clin Endocrinol Metabol 81:3390–3396. https://doi.org/10.1210/jcem.81.9.8784102

Titel: P21Waf1/Cip1 and p27Kip1 are correlated with the development and invasion of prolactinoma
verfasst von: Wei Dong
Jianhua Li
Qian Liu
Chunhui Liu
Chuzhong Li
Guidong Song
Haibo Zhu
Hua Gao
Yazhuo Zhang
Publikationsdatum: 11.12.2017
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2018
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2683-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Parkinson-Krankheit | Podcast | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

P21^Waf1/Cip1 and p27^Kip1 are correlated with the development and invasion of prolactinoma

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Checkpointhemmer auch bei MS sicher

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Toxic effects of phytol and retinol on human glioblastoma cells are associated with modulation of cholesterol and fatty acid biosynthetic pathways

New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model

18F-FDG PET/CT in primary brain lymphoma

Non-pharmacological interventions in patients with spinal cord compression: a systematic review

Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics

Spinal ependymomas in NF2: a surgical disease?

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Checkpointhemmer auch bei MS sicher

Update Neurologie